Clinical Trials Directory

Trials / Completed

CompletedNCT04515550

Mitochondrial Biomarkers in Huntington's Disease

Longitudinal Biospecimen Collection for Mitochondrial Metabolomics in Huntington's Disease

Status
Completed
Phase
Study type
Observational
Enrollment
27 (actual)
Sponsor
University Hospitals Cleveland Medical Center · Academic / Other
Sex
All
Age
20 Years – 85 Years
Healthy volunteers
Accepted

Summary

The objective of this study is to discover a panel of mitochondrial metabolomics biomarkers for Huntington's disease.

Detailed description

This investigator-initiated, single-site longitudinal study seeks to assess the utility of mitochondrial metabolomics -- panels of small molecules that affect mitochondrial function -- to diagnose pre-symptomatic, pre-manifest, and symptomatic Huntington's disease and serve as biomarkers for HD severity and progression. It also seeks to demonstrate that this novel biomarker in the blood has comparable value to the same analysis in spinal fluid. This research study involves 3-4 visits over 18 months. Forty volunteers with HD and 25 volunteers without HD will be included. Volunteers who have HD will have a physical examination and blood draw at each study visit. Some participants will also volunteer for optional lumbar puncture.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTlumbar punctureSome participants will have an optional lumbar puncture

Timeline

Start date
2019-04-04
Primary completion
2022-02-28
Completion
2022-02-28
First posted
2020-08-17
Last updated
2022-04-12

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT04515550. Inclusion in this directory is not an endorsement.